Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Κυριακή 30 Δεκεμβρίου 2018

CD30‐positive cutaneous extranodal natural killer/T‐cell lymphoma: clinicopathological features and survival outcomes

Abstract

Background

The prognostic value of CD30 expression in cutaneous extranodal natural killer/T‐cell lymphoma is controversial.

Methods

Clinicopathological features, survival outcomes, and prognostic implications of CD30 were retrospectively analyzed in 55 patients with cutaneous extranodal natural killer/T‐cell lymphoma. We classified patients into (i) primary cutaneous extranodal natural killer/T‐cell lymphoma and (ii) cutaneous extranodal natural killer/T‐cell lymphoma secondary to nasal disease depending on the primary tumor site.

Results

CD30+ cutaneous extranodal natural killer/T‐cell lymphoma was more common in patients with cutaneous extranodal natural killer/T‐cell lymphoma secondary to nasal disease than in those with primary cutaneous disease. CD30+ cases were more likely to present nodular lesions or cellulitis‐like swelling than CD30− cases. Histologically, CD30+ cutaneous extranodal natural killer/T‐cell lymphoma predominantly comprised large tumor cells compared with CD30− cases. However, the clinical morphology and tumor cell size were not associated with survival outcomes. CD30 expression was associated with better survival outcomes in patients with cutaneous extranodal natural killer/T‐cell lymphoma secondary to nasal disease.

Conclusion

CD30+ cutaneous extranodal natural killer/T‐cell lymphoma presented peculiar clinicopathological features and had more favorable disease course in patients with cutaneous dissemination from nasal disease.



http://bit.ly/2AmWrwS

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου